PE-22-28
Peptide
PE-22-28 is retained as a catalog identity with independently verified primary-literature context. No qualified exposure model, dose recommendation, efficacy claim, or safety claim is provided.
Pharmacokinetic model
A route-level PK model for pe-22-28 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Peptide
- Suggested cadence
- once daily
Research behind this entry
-
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.
This citation reports a laboratory or cell study involving PE-22-28. It does not establish a qualified human dose, safety profile, efficacy claim, or pharmacokinetic route for this catalog record.
1 published study referenced in the app, each with a plain-language summary.